<DOC>
	<DOC>NCT02835105</DOC>
	<brief_summary>This study aims to assess the safety, tolerability, and pharmacokinetics (PK) of a single oral dose of surotomycin (CB-183,315) at ascending dose levels when given to healthy males and females.</brief_summary>
	<brief_title>A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Has no evidence of prior chronic gastrointestinal inflammatory disease such as inflammatory bowel disease or gastroesophageal reflux disease documented on endoscopy Electrocardiogram (ECG) shows no clinically significant abnormalities Is able to swallow capsules is in good health Pregnant or lactating females Has had Clostridium (C.) difficile disease within 1 year prior to entry into the study Has received an investigational drug or participated in any experimental procedure within1 month prior to study entry and at least 6 half lives from last intake of study drug Participants 18 to 49 years of age had taken any regular, prescribed, or overthecounter medication Has any significant concurrent therapies Has a positive drug screen Has a positive human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C screen Has given more than 450 mL of blood (one unit) in the 60 days preceding screening Is an active intravenous drug user or abuses alcohol Has had a malignancy within the last 5 years Has inadequate protection against pregnancy during the conduct of the study and until 1 month after last dose of study drug Has received any antibiotics within 30 days prior to first dose of study drug Has been hospitalized within the past 30 days prior to Study Day 1 Has known hypersensitivity to daptomycin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>